Dozagliptin is a newborn drug belonging to the glucokinase activator class for the treatment of diabetes mellitus, which has the effect of controlling blood glucose and improving the function of patients’ pancreatic islets.
The mechanism of action of Dozagliptin is mainly through the repair of the glucose sensor function defects of glucokinase in diabetic patients, in order to achieve the restoration of impaired blood glucose regulation homeostasis in patients with type 2 diabetes mellitus, the protection of pancreatic islet cells, and improve the pancreatic β-cell function, so as to control the progression of diabetic patients in the clinic.
Dozagliptin is contraindicated in people who are hypersensitive to this product or any of the ingredients in this product. Pre-application precautions: There is a risk of hypoglycemia when the drug is used in combination with insulin or sulfonylureas. Therefore, the specific dosage should be applied regularly and rationally under the guidance of a specialist physician.